Fluoroquinolones are commonly used to treat gastroenteritis caused by Campylobacter species. Domestically acquired fluoroquinolone-resistant Campylobacter infection has been documented recently in the United States. It has been proposed that the increase in resistance is due, in part, to the use of fluoroquinolones in poultry. In separate experiments, the effects of sarafloxacin and enrofloxacin treatment of Campylobacter jejuni-infected chickens on the development of ciprofloxacin resistance were measured. Fecal samples were collected before and after treatment and were cultured for C. jejuni. When enrofloxacin or sarafloxacin was used at US Food and Drug Administration-approved doses in broiler chickens, resistance developed rapidly and persisted in C. jejuni. MICs of ciprofloxacin increased from a base of 0.25 mg/mL to 32 mg/mL within the 5-day treatment time frame. These results show that the use of these drugs in chickens rapidly selects for resistant Campylobacter organisms and may result in less effective fluoroquinolone therapy for cases of human campylobacteriosis acquired from exposure to contaminated chicken.
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Campylobacter jejuni is recognized as the leading cause of bacterial gastroenteritis in the United States, accounting for 2.4 million cases each year [1] . Epidemiologic investigations of sporadic cases have indicated that chicken is the most common source of human infection [2, 3] . In addition, survey data show that Campylobacter species contaminate 80% of retail chicken meats [4] .
Campylobacter infection causes acute inflammatory enteritis that may be indistinguishable from that caused by Salmonella infection. Although Campylobacter enteritis is usually a selflimiting diarrheal disease, infrequent cases of serious invasive or relapsing illness, particularly in immunocompromised patients, may require antibiotic therapy. When antimicrobials are used to treat adults with enteritis, they are most effective in limiting the duration of illness when given early in the course of infection, before the etiologic agent is confirmed by culture [5] . Because fluoroquinolones are commonly used to treat persons with Campylobacter infections, the emergence of resistant strains will limit the therapeutic usefulness of these drugs.
The fluoroquinolones sarafloxacin and enrofloxacin were licensed in 1995 and 1996, respectively, for controlling mortality associated with Escherichia coli infections in chickens. Both antimicrobials are administered to the entire chicken house ad libitum in water for up to 5 days for sarafloxacin and for 5-7 days for enrofloxacin. Surveillance data suggest a temporal association between the approval of these drugs in poultry and increased resistance in Campylobacter isolates from human infections [6, 3] . To measure the impact of fluoroquinolone use in chickens on resistance development in C. jejuni, experimentally infected animals were medicated with sarafloxacin or enrofloxacin. C. jejuni isolates were collected over time, and fluoroquinolone MICs were measured.
Materials and Methods
Newly hatched broiler chicks from a commercial source were allocated randomly to 2 groups of 50 (sarafloxacin treated) or 25 (enrofloxacin treated) birds each. The chickens were reared under conventional conditions on pine-shave bedding with continuous lighting. Animals were fed a standard antibiotic-free broiler starter/ grower diet, which was prepared on site, and were given access to feed and water ad libitum. To help insure that exogenous Campylobacter species were not introduced via the feed, 20 feed samples were collected at approximately equal intervals from the mixer exit stream immediately after preparation of feed and were cultured using standard methods [7] .
A collection of C. jejuni chicken isolates obtained from the University of Maryland was screened for fluoroquinolone susceptibility. Five fluoroquinolone-susceptible isolates were identified, each with the following MICs: ciprofloxacin, 0.25 mg/mL; sarafloxacin, 0.125 mg/mL; and enrofloxacin, 0.06 mg/mL. A mixture containing an equal number of all 5 strains (1 £ 10 6 cfu total) was given to each bird as a 0.2-mL gavage deposited directly into the crop, using a long-tipped pipette. Since chickens are usually colonized with Campylobacter species after 2 weeks of age, the birds were inoculated orally at either 16 (sarafloxacin treated) or 24 (enrofloxacin treated) days of age. The birds remained free of Campylobacter species until deliberately infected.
The experiments using sarafloxacin and enrofloxacin were conducted separately. After inoculation with C. jejuni, birds were medicated with either sarafloxacin hydrochloride (SaraFlox WSP; Abbott Laboratories) or enrofloxacin (Baytril; Bayer). In each experiment, half the birds received fluoroquinolone-containing water beginning at 30 days of age, and the other half served as C. jejunicolonized, nonmedicated controls. Both compounds were administered at 40 ppm (40 mg/mL) in drinking water for 5 consecutive days.
In the sarafloxacin study, fecal samples were collected just before treatment (day 0) and 5, 7, 9, 12, 19, and 26 days after starting treatment. In the enrofloxacin study, fecal samples were collected just before treatment and 1, 3, 5, 12, and 21 days after starting treatment. In both studies, 50 freshly voided fecal samples (25 each from the treated and control groups) were collected on each sampling day. The 25 samples were combined into 5 composite samples of 5 individual samples each. This resulted in a total of 35 composite samples from the sarafloxacin-treated birds and 30 composite samples from the enrofloxacin-treated birds. These composites were cultured for C. jejuni.
Each composite sample was diluted 1:2 (wt/vol) with 0.1% peptone-buffered water and was mixed thoroughly by vortexing. Two hundred microliters from each homogenate was used to inoculate Bolton Broth (Oxoid) and was incubated at 42 C for 24 h, using the CampyPak Microaerophilic System (BBL). Bolton broths were streaked onto agar (Campy Cefex; Hardy Diagnostics) to provide isolated colonies and were incubated for 24 h at 42 C, using the CampyPak system. After incubation, 10 typical colonies from each composite sample were confirmed as C. jejuni by use of Gram's staining and the AccuProbe Campylobacter Culture Identification Test (GenProbe) and then were frozen at 280 C for subsequent susceptibility testing. Thus, 50 isolates from each pen per collection day were subjected to agar-dilution susceptibility testing.
In vitro susceptibility testing was done by agar dilution, in accordance with guidelines from the National Committee for Clinical Laboratory Standards (NCCLS) [8] , using C. jejuni ATCC 33560 as the quality-control organism. An agar-dilution method using this organism has received NCCLS approval for susceptibility testing of C. jejuni. Tentative quality-control ranges for ciprofloxacin are 0.125-1.0 mg/mL. Test medium consisted of Mueller-Hinton agar containing 5% defibrinated sheep blood. Thirteen fluoroquinolone concentrations (range, 0.015-64 mg/mL) were tested. Sarafloxacin was obtained from Abbott Laboratories, enrofloxacin was obtained from Bayer, and ciprofloxacin was purchased from Miles. Plates were incubated for 48 h at 35 C-37 C in an atmosphere containing 5% O 2 , 10% CO 2, and 85% N 2 .
Results
Campylobacter species were not isolated from any composite fecal samples collected before oral inoculation of the birds. In addition, no Campylobacter species was found in the 20 feed samples tested. After inoculation and fluoroquinolone treatment, Campylobacter species were isolated from every composite sample tested throughout the course of the experiments.
The changes in Campylobacter fluoroquinolone MICs over time are shown in figure 1. The highest MICs observed during the course of the studies were 32 mg/mL for ciprofloxacin, 64 mg/mL for sarafloxacin, and 8 mg/mL for enrofloxacin. Twenty-four hours after initiating enrofloxacin treatment, 100% of the isolates from the enrofloxacin-treated group (figure 1A) had maximum MICs for ciprofloxacin (32 mg/mL) and enrofloxacin (8 mg/mL). In the sarafloxacin-treated birds, the first samples were collected on day 5 of treatment. All these isolates also displayed ciprofloxacin MICs of 32 mg/mL and sarafloxacin MICs of 32-64 mg/mL (expressed as >32 mg/mL; figure 1B ). In the nontreated controls in both studies, the Campylobacter Figure 1 . Changes in fluoroquinolone MICs after enrofloxacin (A) or sarafloxacin (B) treatment. In isolates from enrofloxacin-treated birds (A), MICs of ciprofloxacin and enrofloxacin peaked at 32 mg/ mL and 8 mg/mL, respectively. In isolates from the sarafloxacin-treated birds (B), ciprofloxacin MICs again peaked at 32 mg/mL, and sarafloxacin MICs were either 32 mg/mL or 64 mg/mL (expressed as >32 mg/ mL for comparative purposes). No isolates from the nontreated control groups displayed ciprofloxacin MICs .0.5 mg/mL. Each data point represents the susceptibility results of 50 Campylobacter jejuni isolates. Day 0 indicates initiation of fluoroquinolone treatment. Arrows indicate duration of medication (5 days).
fluoroquinolone MICs remained within a 2-fold dilution of the pre-exposure values.
After the cessation of enrofloxacin treatment, all isolates maintained the maximum MICs for both enrofloxacin and ciprofloxacin throughout the sampling period ( figure 1A) . In contrast, isolates from the sarafloxacin-exposed birds showed an increase in the proportion of susceptible isolates beginning on day 12 (figure 1B). Ciprofloxacin MICs were usually 0.25 or 32 mg/mL, with few intermediate phenotypes. In addition, the correlation of ciprofloxacin MICs with sarafloxacin and enrofloxacin was 100% in both cases. Thus, ciprofloxacin MICs for C. jejuni are predictive of fluoroquinolone resistance resulting from use of the veterinary-specific fluoroquinolones in broiler chickens.
Discussion
Ciprofloxacin has been used to treat human bacterial infections since 1986; however, domestically acquired resistance did not emerge among Campylobacter species in the United States until 1996 and 1997, soon after the approval of fluoroquinolones for use in poultry [3] . Studies in The Netherlands also have shown a significant increase in fluoroquinolone resistance among human isolates since the introduction of enrofloxacin into veterinary medicine [6] . This phenomenon has raised the concern that fluoroquinolone-resistant Campylobacter species can be transferred to humans consuming contaminated poultry products, resulting in human campylobacteriosis that is less responsive to fluoroquinolone therapy.
Surveillance data indicate that 80% of retail chicken may be contaminated with Campylobacter species [4] . A recent study showed that 27% of Campylobacter species-contaminated retail chicken products carried a fluoroquinolone-resistant strain [9] . In addition, among domestically acquired campylobacteriosis cases in the United States, poultry has been identified as the most likely source of the fluoroquinolone-resistant Campylobacter species infecting humans [3] .
Our results show that the use of fluoroquinolones in broiler chickens generates a rapid increase in the fluoroquinolone MICs of resident C. jejuni (32 mg/mL), which appears within the treatment time frame and persists long after treatment is stopped. No resistant isolates were detected in the nontreated control groups. In the case of C. jejuni from animals treated with sarafloxacin, an increased proportion of susceptible isolates appeared beginning at day 12. At day 26 (3 weeks after ending treatment), 72% of the isolates tested displayed MICs >32 mg/mL. In contrast, 100% of isolates analyzed from the enrofloxacin-treated animals displayed ciprofloxacin MICs of 32 mg/mL throughout the experiment, which ended 16 days after the end of treatment. Similar results from enrofloxacin-treated birds were reported by Jacobs-Reitsma et al. [10] . Using disk diffusion testing, they observed decreased enrofloxacin susceptibility on the fourth (final) day of treatment in 16 C. jejuni isolates that were assayed, and the decreased susceptibility persisted for 2 weeks after treatment. Since they did not report MICs, the magnitude of the shift could not be determined.
A main goal of the present study was to quantify changes in susceptibility among isolates from treated animals and to compare the MICs of ciprofloxacin with the veterinary-specific fluoroquinolones sarafloxacin and enrofloxacin. Our results support the finding of Jacobs-Reitsma et al. [10] that fluoroquinolones do not eliminate Campylobacter species from the intestinal tract of chickens, but rapidly select for fluoroquinolone-resistant isolates.
The distribution of fluoroquinolone MICs in Campylobacter species isolates appears to be bimodal. Among Campylobacter species isolates submitted to the US National Antimicrobial Resistance Monitoring System, MICs were predominantly <0.15 or >32 mg/mL, with very few intermediate phenotypes [11] . A similar distribution is seen among the isolates tested in our study. It is known that a single point mutation in the gyrA gene is sufficient to confer high-level ciprofloxacin MICs in Campylobacter species [12] . This could explain both the bimodal nature of the phenotype and the rapid emergence of resistance in Campylobacter organisms from treated animals.
Because fluoroquinolones act by inhibiting DNA gyrase, crossresistance between different agents in the fluoroquinolone class is expected. Our data show that the MICs of sarafloxacin and enrofloxacin are predictive of susceptibility to ciprofloxacin. Allowing for a variability of^1 dilution range, the MICs between ciprofloxacin and the veterinary fluoroquinolones showed 100% correlation in C. jejuni, indicating that the susceptibility levels for ciprofloxacin directly reflect the use of the veterinary-specific agents.
It has been shown that fluoroquinolone concentrations near or below the MIC are more apt to select for fluoroquinoloneresistant bacteria [13] . This property of resistance development, along with the fact the Campylobacter organisms are intrinsically less susceptible to quinolone agents, is particularly important in light of modern poultry production practices. The current method of medicating chickens is by treating the entire house via water, even though relatively few birds may be ill. This practice exposes more organisms to the antimicrobial and therefore is more likely to result in the emergence of resistant strains. An additional problem arises because the dose received by the animals varies, since the antimicrobial is administered in water ad libitum. This may result in suboptimal dosing and may increase the probability of selecting for resistant Campylobacter strains in both healthy and diseased birds.
In summary, our results show that the use of veterinaryspecific fluoroquinolones in chickens generates a rapid increase in the ciprofloxacin MICs of C. jejuni (from 0.250 mg/mL to 32 mg/mL) and that this increase appears within the treatment time frame and persists long after treatment is stopped. In accordance with Food and Drug Administration guidelines, there is a 2-day preslaughter drug withdrawal period for enrofloxacin and none for sarafloxacin. Our findings indicate that these withdrawal times are not adequate to reduce the prevalence of resistant Campylobacter species, since resistant strains can be recovered from chickens 3 weeks after ending treatment. Contamination of poultry carcasses during processing would thus result in the presence of fluoroquinolone-resistant Campylobacter species on meats derived from treated birds. These results highlight the potential consequences of medicating animals with antimicrobials important to human medicine. The continued use of these drugs in poultry has the potential to further limit therapeutic options available for treating human campylobacteriosis infections.
